Mylan Gets Until April 2020 To Decide On Biosimilar Botox Collaboration With Revance

 
• By Akriti Seth

Revance has amended its agreement with Mylan to collaborate on a rival version of Botox to give Mylan more time to decide on whether it wants to continue developing the biosimilar. In turn, Mylan has agreed to pay $5m to Revance for the extended deadline.

2020
Revance extends Mylan’s deadline to April 2020 in exchange for $5m • Source: Shutterstock

More from Deals

More from Business